Latest News and Press Releases

PORTOLA VALLEY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announces two pre-clinical studies published in the...

60 Degrees Pharma survey suggests babesiosis affects up to 3M Americans—vastly more than CDC data—and may underlie millions of chronic fatigue cases.

60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited treatments.

60 Degrees Pharmaceuticals announces IRB approval for Phase II study of tafenoquine for chronic babesiosis, with enrollment starting Q3 2025.

60 Degrees Pharma and Tufts MC partner to develop tafenoquine for babesiosis, co-own patents, and aim for FDA approval to address unmet medical needs.

PORTOLA VALLEY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announces the recipient of the 2024 Emerging Leader Award...

PORTOLA VALLEY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced it has united efforts with Twin Cities Lyme...

PALO ALTO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced a study finding a new mechanism of immune...

PORTOLA VALLEY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, recently announced publication of a laboratory study...

PORTOLA VALLEY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, recently announced publication of a laboratory study showing...